AIDSWEEKLY Plus; Monday, December 23, 2002
Michael Greer, Senior Medical Writer
"Efficient replication and gene expression of human immunodeficiency virus-1 (HIV-1) involves specific interaction of the viral protein Tat, with its trans-activation responsive element (TAR), which forms a highly stable stem-loop structure," according to Neerja Kaushik and colleagues at the University of Medicine and Dentistry of New Jersey's Center for the Study of Emerging and Re-Emerging Pathogens in Newark.
Kauskik and coauthors found that a polyamide nucleotide analog (PNA) could disrupt the Tat-TAR interaction and short-circuit the HIV replication process.
The researchers developed four PNAs targeting the loop and bulge region of HIV TAR. Two of these nucleotide analogs (PNATAR-15 and PNATAR-16) complemented the entire region, while the other two (PNATAR-13 and PNATAR-12) lacked several sequences complementing the loop and/or bulge, according to the report.
The 15- and 16-mer PNAs proved able to efficiently prevent Tat from interacting with TAR's loop and bulge, study data showed. PNATAR-16 reduced HIV virion production by almost 99% in infected cell cultures.
Although the shorter PNAs demonstrated strong affinity for TAR RNA, they had a less pronounced impact on viral replication (Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res 2002 Oct;56(1):13-27.
"These results point to PNATAR-16 as a potential anti-HIV agent," Kaushik and colleagues concluded.
The corresponding author for this report is Virendra N. Pandey, Department of Biochemistry and Molecular Biology, Center for the Study of Emerging and Re-Emerging Pathogens, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103 USA. E-mail: pandey@umdnj.edu.
A search at www.NewsRx.net using the search term "AIDS and HIV therapy" yielded 1193 articles in 29 specialized reports.
Key points reported in this study include:
A polyamide nucleotide analog (PNA) disrupts HIV transactivation activity
The 16-mer PNA prevents HIV Tat from interacting with the viral transactivation responsive element (TAR)
This PNA reduced HIV replication by almost 99%
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Kaushik N, Basu A, Pandey VN., "Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog", Antiviral Res 2002 Oct;56(1):13-27.
021223
AW021213
Copyright © 2002 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.